Notes

Sentiment group for employees testimonials making use of regression vector- stochastic incline descent classifier (RV-SGDC).
ed the most accurate alignment between CBCT and CT images. Satisfactory registration results of anatomical structures do not guarantee a correct mapping of primary BRT doses on the bladder delineated on CT images during EBRT. selleck compound The results of dose transformation based on biomechanical registration had an error of less than 5% for only 50% of the observations.
AccuBoost is a complex non-invasive brachytherapy procedure for breast treatment. This technique requires a radiation oncologist to manually select applicator grid position and size by overlaying transparencies over a mammographic image to encompass surgical clips and resected tumor bed. An algorithm was developed in MATLAB™ to automate the selection of round applicators based on surgical clip position.

A total of 42 mammograms belonging to 10 patients were retrospectively analyzed. Images were pre-processed by masking imprinted localization grid and regions around the grid. A threshold was applied to isolate high-intensity pixels and generate a binary image. A set of morphological operations including region dilation, filling, clearing border structures, and erosion were performed to segment the different regions. A support vector machine classification model was trained to categorize segmented regions as either surgical clips or miscellaneous objects based on different region properties (area, perimeterition to clip position.
The proposed algorithm provided a method to quantitatively determine applicator position and size for AccuBoost treatments, and may serve as a tool for independent verifications. The discrepancy between physician-selected and algorithm-predicted determinations of applicator position and size suggests that the methodology may be further improved by considering radiomic features of breast tissue in addition to clip position.
To analyze factors influencing the efficacy of
I seed implantation in the treatment of in-field cervical lymph node recurrence of esophageal squamous cell carcinoma (ESCC) after external beam radiation therapy.

We conducted a retrospective review of 36 patients with in-field cervical metastatic lymph nodes recurrence of esophageal squamous cell carcinoma (CML-ESCC) after external beam radiation therapy treatment, who underwent
I seed implantation in our department from 2013 to 2019. Previous cumulative external irradiation dose ranged from 20 to 66 Gy (median, 60 Gy). The post-implant efficacy was evaluated by response evaluation criteria in solid tumors (RECIST) version 1.1, and an adverse event was evaluated by the Radiation Therapy Oncology Group (RTOG)/European Organization for Research and Treatment of Cancer Late Radiation Morbidity Score (EORTC). COX proportional hazards model was used to analyze risk factors affecting effectiveness.

Among 36 patients, 31 patients (86.1%) received fluorouraci-field cervical lymph node recurrence of ESCC after external beam radiation therapy.
The purpose of this study was to evaluate long-term treatment outcomes and prognostic factors affecting survival of patients with early-stage endometrial carcinoma.

Data of 311 patients with FIGO stage I-II endometrial cancer, curatively treated at two different tertiary centers between June 2001 and December 2016 were retrospectively reviewed. The patients had primary surgery, 74 (24%) received no further treatment, 4 (1%) obtained chemotherapy only, 234 (75%) received radiotherapy, and 24 (7%) received both.

Median follow-up time was 102 (range, 3-205) months. During this period, 68 (21.9%) patients died. 5-year and 10-year disease-free survival (DFS) were 76% and 74.3%, respectively. In multivariate analysis, lower uterine segment invasion positivity and no adjuvant radiotherapy were determined as independent unfavorable prognostic factors for DFS. The 5-year and 10-year disease-specific survival (DSS) were 86.8% and 82.2%, respectively. For DSS, high-grade, lymphovascular space invasion positivity, stage II, ≥ 65 age, and no adjuvant radiotherapy were found to be independent unfavorable prognostic markers.

The findings of our cohort have confirmed the importance of adjuvant radiotherapy on long-term early-stage endometrial carcinoma outcome.
The findings of our cohort have confirmed the importance of adjuvant radiotherapy on long-term early-stage endometrial carcinoma outcome.
Intracavitary vaginal brachytherapy (VBT) cylinders are limited in treating upper/apical vaginal disease due to the distance between the target and radiation source positions. Interstitial brachytherapy devices directly expose the vaginal mucosa to radiation sources, increasing morbidity. To target apical disease while limiting excessive treatment to the vaginal mucosa and organs at risk, we modified the commercially available multichannel MIAMI applicator, allowing the direct extension of needles into the apex with the protection of cylinder.

The device has one central plastic core with six peripheral channels. The modified device permits titanium needles to surpass the apical surface into vaginal tissue. A retrospective analysis on thirteen patients treated with this device was conducted. Patient demographics, gross tumor volume (GTV)/clinical target volume (CTV), initial diagnosis and management, toxicity data, and EQD
data for the bladder and rectum were obtained.

There were ten patients with vagiariable vaginal diameters and sizes/depths of apical tumors using a single device.
Our data suggests that the custom applicator is associated with robust dosimetric coverage, good loco-regional control, acceptable toxicity, and reduced tissue trauma. This device allows treatment of apically located vaginal tumors without significant damage to the vaginal vault and organs at risk. Additionally, it provides the flexibility to treat multiple patients with variable vaginal diameters and sizes/depths of apical tumors using a single device.
To prospectively investigate the efficacy and feasibility of focal low-dose-rate (LDR) prostate brachytherapy for low- and intermediate-risk prostate cancer.

Between October 2014 and May 2019, nineteen low- and intermediate-risk prostate cancer patients who presented with abnormality on both diffusion-weighted and T2-weighted magnetic resonance imaging (MRI) underwent focal LDR brachytherapy at our institution. Focal gross tumor volume (F-GTV) was delineated on transrectal ultrasound, based on abnormality seen on fused T2-weighted MRI. F-GTV was expanded by 5 mm, as a safety margin, to create focal clinical target volume (F-CTV). Prescribed dose to F-CTV was 145 Gy. Biochemical recurrence (BCR) was determined using Phoenix criterion (prostate specific antigen nadir + 2 ng/ml). Pre- and post-implant dosimetry data were compared using non-parametric Wilcoxon's rank sum test. Treatment-related toxicities were evaluated using common terminology criteria for adverse events.

Mean F-CTV D
was significantly lower in the post-implant evaluation than in intraoperative planning (
= 0.
My Website: https://www.selleckchem.com/products/ono-7475.html